Table 1.
Univariate analyses in clinicopathological characteristics of EGC meeting different indications
| Absolute indication (N = 421) | Expanded indication (N = 746) | Relative indication (N = 1,346) | P—univariate analysis | |
| PAC | 51 (12.4%) | 89 (11.8%) | 195 (14.5%) | 0.179 |
| Sex, N (%) | <0.001 | |||
| Male | 318 (77.2%) | 533 (70.6%) | 889 (66.0%) | |
| Female | 94 (22.8%) | 222 (29.4%) | 457 (34.0%) | |
| Age, N (%) | <0.001 | |||
| <60 yr | 116 (28.2%) | 313 (41.5%) | 544 (40.4%) | |
| ≥60 yr | 296 (71.8%) | 442 (58.5%) | 802 (59.6%) | |
| Tumor location, N (%) | 0.598 | |||
| Upper stomach | 180 (43.7%) | 307 (40.7%) | 566 (42.1%) | |
| Lower stomach | 232 (56.3%) | 448 (59.3%) | 780 (57.9%) | |
| Tumor size, cm, N (%) | <0.001 | |||
| ≤2.0 | 412 (100.0%) | 522 (69.1%) | 649 (48.2%) | |
| >2.0 | 0 (0.0%) | 233 (30.9%) | 697 (51.8%) | |
| Ulceration, N (%) | 0 (0.0%) | 147 (19.5%) | 362 (26.9%) | <0.001 |
| Differentiation, N (%) | <0.001 | |||
| Well/moderate | 412 (100.0%) | 496 (65.7%) | 519 (38.6%) | |
| Poor | 0 (0.0%) | 259 (34.3%) | 827 (61.4%) | |
| Gross pattern, N (%) | <0.001 | |||
| 0–I + IIa | 68 (16.5%) | 124 (16.4%) | 232 (17.2%) | |
| 0–IIb | 175 (42.5%) | 239 (31.7%) | 271 (20.1%) | |
| 0–IIc + III | 169 (41.0%) | 392 (51.9%) | 843 (62.6%) | |
| Invasion depth, N (%) | <0.001 | |||
| M | 412 (100.0%) | 519 (68.7%) | 232 (17.2%) | |
| SM1 | 0 (0.0%) | 236 (31.3%) | 260 (19.3%) | |
| SM2 | 0 (0.0%) | 0 (0.0%) | 854 (63.4%) | |
| Necrosis, N (%) | 116 (28.2%) | 235 (31.1%) | 472 (35.1%) | 0.017 |
| Micropapillary adenocarcinoma, N (%) | 0 (0.0%) | 2 (0.3%) | 28 (2.1%) | <0.001 |
| LVI, N (%) | 0 (0.0%) | 1 (0.1%) | 345 (25.6%) | <0.001 |
| Perineural invasion, N (%) | 1 (0.2%) | 3 (0.4%) | 113 (8.4%) | <0.001 |
| LNM, N (%) | 4 (1.0%) | 49 (6.5%) | 311 (23.1%) | <0.001 |
Upper stomach: cardia, body, and fundus; lower stomach: angle, antrum, and pylorus.
EGC, early gastric carcinoma; LNM, lymph node metastasis; LVI, lymphovascular invasion; M, confined to mucosa; PAC, papillary adenocarcinoma; SM1, <500 μm from the muscularis mucosae; SM2, confined to the submucosa and >500 μm from the muscularis mucosae.